| Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
|
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
| Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
|
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
| A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium |
|
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
| A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium |
|
Journal of Pediatric Hematology/Oncology (JPHO) |
Aplastic Anemia |
| Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
|
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
